Merck and Moderna announced on Wednesday that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's Keytruda, met both primary and secondary endpoints in the Phase 3 INTerpath-001 trial. The study enrolled more than 1,100 patients with completely resected stage IIB-IV melanoma and found statistically significant improvements in recurrence-free survival and distant metastasis-free survival compared to Keytruda alone.
This is the first positive Phase 3 readout for an individualized neoantigen mRNA therapy in history. The implications extend well beyond melanoma.
How the Vaccine Works
Intismeran autogene is designed and manufactured for each patient individually. After surgical tumor removal, the patient's tissue undergoes whole exome and RNA sequencing. Machine learning algorithms then identify up to 34 neoantigens unique to that patient's tumor. These sequences are encoded into a single mRNA construct, formulated into lipid nanoparticles, and delivered via intramuscular injection.
The idea is to train the immune system to recognize cancer markers specific to that patient's disease, then pair the trained response with Keytruda, which blocks the PD-1 checkpoint and allows T cells to attack tumor cells more effectively. The entire manufacturing process takes weeks from biopsy to administration.
The Phase 2b KEYNOTE-942 trial, whose five-year follow-up data were presented at ASCO 2026, showed a 49% reduction in the risk of recurrence or death compared to Keytruda alone. That data set built confidence in the approach and informed the design of the larger Phase 3 trial that just reported positive results.
The manufacturing success rate in earlier trials exceeded 99% for patients whose neoantigen design succeeded, and no new safety signals have emerged. Side effects have reportedly been similar to those of other vaccines patients routinely receive.
The INTerpath Program Expands
Merck and Moderna are running nine total Phase 2 and Phase 3 clinical trials evaluating intismeran in combination with Keytruda across multiple tumor types. In addition to melanoma, active studies include non-small cell lung cancer, bladder cancer, and renal cell carcinoma. A Phase 1 study is also exploring adjuvant treatment in pancreatic ductal adenocarcinoma and gastric carcinoma.
The companies said they will present full data from INTerpath-001 at an upcoming international medical meeting and intend to engage with regulators on filing submissions. Analysts at Citi had set a hazard ratio at or below 0.65 as representing a clear win for the trial, though the companies have not yet released the specific figure.
AI and the Acceleration of Precision Medicine
The success of this trial arrives at a moment when artificial intelligence is compressing timelines across drug discovery and development. Personalized vaccines require identifying which tumor mutations will provoke an immune response. That prediction problem has been transformed by deep learning models trained on peptide MHC binding, antigen processing, and T cell receptor recognition.
Platforms like AlphaFold 3 and its successor, IsoDDE from Isomorphic Labs, have doubled the accuracy of protein-ligand binding predictions in difficult cases. These tools are enabling researchers to model complex molecular interactions computationally rather than running endless wet lab experiments. Drug Discovery Online recently noted that AI is no longer optional for competitive discovery.
But there are limits. As of mid-2026, no AI-native drug has completed the full FDA approval process. The field has proven that AI can accelerate discovery and generate clinical candidates faster and more cheaply than traditional approaches. It has not yet proven that AI-discovered drugs perform better in late-stage trials or receive approval at higher rates. Clinical trials remain the bottleneck. Biology, not computation, determines efficacy.
The gap matters. Moderna and Merck's vaccine benefits from AI in the neoantigen selection process, but the hard work of validating safety and efficacy across thousands of patients took years. The Phase 2b trial began enrolling in 2019. The Phase 3 results arrived in 2026.
What Comes Next
If approved, intismeran would be the first mRNA-based individualized cancer therapy to reach the market. That distinction carries weight. The COVID-19 vaccines proved mRNA could be manufactured at scale and delivered safely to billions of people. Extending that platform to oncology has been the next obvious step for years, but clinical validation was always the question mark.
Merck and Moderna have now answered it, at least for adjuvant melanoma. Whether similar results hold across other tumor types will determine whether personalized mRNA vaccines become a routine part of cancer care or remain limited to specific indications. The INTerpath program is designed to find out.
BioNTech and Memorial Sloan Kettering have shown promising results in pancreatic cancer with their own personalized mRNA approach. Other companies are exploring similar strategies. The field is no longer theoretical. It is entering the phase of validation across multiple disease contexts.
The overall survival data from INTerpath-001 are still maturing. The 1,137-patient study will continue to assess that endpoint. For now, the recurrence-free and distant metastasis-free survival improvements are sufficient for the companies to pursue regulatory discussions.
